Collecting blood samples to improve a blood test for early detection of colorectal cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study will prospectively collect blood samples and clinical data from three groups: people newly diagnosed with colorectal cancer who are pre-treatment (including those scheduled for resection and those with histologic confirmation but not scheduled for surgery) and average-risk adults undergoing routine screening colonoscopy. The sponsor has identified circulating free DNA alterations—such as methylation patterns, fragmentation signatures, and copy-number changes—to form a preliminary marker panel. Samples from the US population will be used to optimize and finalize the panel and to characterize its performance for detecting CRC and advanced precancerous lesions. No investigational treatment is given; the protocol centers on specimen collection and clinical data linkage for assay development.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Arm A: Diagnosed with CRC
* Arm B: Undergoing screening with colonoscopy for CRC

Exclusion Criteria:

* Arm A: Undergoing treatment for CRC,
* Arm B: Past history of CRC

Where it's running

• Gastroenterology and Internal Medicine Specialists
  Lake Barrington, Illinois, United States Recruiting

Study contacts

• Study coordinator: Antonio Jesus Merino Calvo
• Email: antonio.merino@universaldx.com
• Phone: 674945571

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Knife-assisted full-thickness resection for rectal lesions in a multicenter setting

  A multicenter study tests knife-assisted full-thickness resection (kFTR) to remove rectal lesions in adults and see how well it works and how safe it is.

  Recruiting University Hospital, Ghent · Ghent · NCT07923682

• Personalized 3D Bioprinted Colorectal Cancer Microenvironment Model

  This study tests patient-derived, 3D-bioprinted cancer models that include tumor, fibroblast, and immune cells to see if they can better predict how colorectal cancer will respond to treatment.

  Recruiting Peking Union Medical College Hospital · Ningbo, Zhejiang · NCT07919418

• Integrated genomic and clinical database for cancer biomarker discovery

  Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.

  Recruiting Samsung Medical Center · Seoul, Gang-Nam · NCT07911267

• Prehabilitation with Resistance, Aerobic, or Both Before Colorectal Surgery

  Four pre-surgery exercise options (resistance, aerobic, both, or none) will be tested to see which best reduces complications after colorectal cancer surgery.

  Recruiting Semmelweis University · Budapest · NCT07896174

• Liver transplantation for colorectal cancer with liver metastases

  This study follows adults with stage IV colorectal cancer whose disease is limited to the liver and who are getting a liver transplant as part of their cancer care to see how they fare over time.

  Recruiting Pontificia Universidad Catolica de Chile · Santiago, Santiago Metropolitan · NCT07884110

• LTZ-232: a first-in-human test in advanced colorectal and other solid tumors

  A first-in-human study tests LTZ-232, a new therapy for adults with unresectable or metastatic colorectal cancer and other solid tumors that have not responded to standard treatments.

  Recruiting Phase 1 LTZ Therapeutics, Inc. · Scottsdale, Arizona · NCT07878988

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.